Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet-activating factor in surfactant preparations

F R Moya1, D R Hoffman, B Zhao

  • 1Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235.

Lancet (London, England)
|April 3, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Curcumin monomer regulates ferroptosis via the melatonin receptor 2/cyclic adenosine monophosphate/protein kinase A/inositol-requiring enzyme 1 pathway to treat ischemic stroke.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2026
Same author

[Popularity characteristics of respiratory syncytial virus infection in children aged 5 years and under in Pudong New Area, Shanghai, 2013-2023].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2025
Same author

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

ESMO open·2025
Same author

[The clinical and imaging presentations of the pontine tegmental cap dysplasia].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2025
Same author

Unravelling the molecular recognition mechanism between odorants and PBP1 in <i>Loxostege sticticalis</i> by homology modelling, molecular docking, and MD simulation.

SAR and QSAR in environmental research·2025
Same author

[Research progress in diabetic lumbosacral radiculoplexus neuropathy].

Zhonghua nei ke za zhi·2025
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Neonatal surfactant treatments may contain platelet-activating factor (PAF), a lung mediator. Animal-derived surfactants had detectable PAF levels, potentially impacting infant respiratory distress syndrome treatment.

Area of Science:

  • Neonatology
  • Pulmonology
  • Biochemistry

Background:

  • Surfactant replacement therapy is a cornerstone in managing neonatal respiratory distress syndrome (RDS).
  • Platelet-activating factor (PAF) is a potent lipid mediator implicated in inflammatory and physiological processes within the fetal lung.
  • The presence and potential impact of PAF in clinical surfactant preparations remain underexplored.

Purpose of the Study:

  • To investigate the presence and quantity of platelet-activating factor (PAF) in commonly used surfactant preparations.
  • To assess the potential physiological significance of administered PAF in the context of neonatal respiratory distress syndrome (RDS).

Main Methods:

  • Quantification of PAF in three animal-derived surfactant preparations using sensitive analytical techniques.

Related Experiment Videos

  • Comparison of PAF levels in natural surfactants versus an artificial surfactant.
  • Assessment of PAF-acetylhydrolase activity in tracheal fluid from infants with RDS.

    • Main Results:

    • Three animal-derived surfactant preparations contained significant levels of PAF, ranging from 36 to 218 pmol/mL.
    • PAF was undetectable in an artificial surfactant preparation.
    • Calculated doses of natural surfactant could administer 144-654 pmol PAF, potentially exerting physiological effects.
    • Infants with RDS exhibited low PAF-acetylhydrolase activity in tracheal fluid, suggesting impaired PAF inactivation.

    Conclusions:

    • Commercially available animal-derived surfactant preparations contain biologically relevant amounts of PAF.
    • The presence of PAF in surfactant therapy may contribute to lung pathophysiology in neonates with RDS.
    • Reduced PAF-inactivating capacity in RDS infants could exacerbate the effects of administered PAF, warranting further investigation.